Testicular Cancer

Testicular cancer arises from germ cell transformation through malignant dedifferentiation and loss of normal growth constraints

• Carcinoma in situ (intratubular germ cell neoplasia unclassified, IGCNU) as precursor lesion: Nearly all testicular germ cell tumors originate from IGCNU, a preinvasive neoplastic lesion arising from primordial germ cells during embryogenesis or postnatal development. IGCNU cells exhibit loss of normal apoptotic mechanisms, silencing of tumor suppressors (particularly p53 and PTEN), and hypermethylation of the p16 promoter. These cells remain confined to seminiferous tubules initially but progress to invasive cancer through acquisition of additional genetic alterations including mutations in KIT proto-oncogene (present in ~40% of seminomatous tumors), amplification of chromosome 12 (pathognomonic i(12p) isochromosome in ~80% of germ cell tumors), and alterations in genes controlling cell cycle regulation. The transition from IGCNU to invasive disease represents the critical malignant step, though the median time to progression remains uncertain.

• Chromosome 12 amplification and oncogenic transformation: The isochromosome 12p (i(12p)) results from duplication of the short arm of chromosome 12 with loss of the long arm, creating a supernumerary chromosome with extra copies of genes including KRAS, CCND2 (cyclin D2), and CDK2. This amplification promotes uncontrolled cell proliferation through increased cyclin-dependent kinase activity, drives resistance to apoptosis, and is virtually pathognomonic for germ cell tumors. Alternative mechanisms of chromosome 12 amplification (including tetrasomy 12p or other rearrangements) occur in some tumors lacking i(12p). The presence of i(12p) is both a hallmark of malignant transformation and a marker of aggressive biology requiring intensive treatment.

• Histological differentiation spectrum and its molecular basis: The histological manifestations of testicular cancer (seminoma vs. non-seminomatous germ cell tumor [NSGCT] subtypes) result from differential expression of developmental genes and epigenetic modifications. Seminomas retain a relatively undifferentiated state with persistent expression of pluripotency factors (OCT4, NANOG, SOX2) and show relatively simpler karyotypes with i(12p) as the primary recurrent abnormality and KIT mutations in ~40% of cases. Non-seminomatous tumors (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma) represent more differentiated lineages with expression of lineage-specific markers and typically more complex chromosomal abnormalities beyond i(12p). Embryonal carcinoma represents the pluripotent stem cell component; yolk sac tumor represents endodermal differentiation with production of α-fetoprotein (AFP); choriocarcinoma represents trophoblastic differentiation with production of β-human chorionic gonadotropin (β-hCG); teratoma represents embryonic tissue differentiation. The molecular events driving lineage commitment remain incompletely understood but involve alterations in transcription factors and epigenetic remodeling.

• Loss of normal apoptotic checkpoints and tumor suppressor dysfunction: Testicular germ cell tumors demonstrate marked chemosensitivity despite aggressive biology, a paradox reflecting retained functional apoptotic pathways that can be activated by chemotherapy. However, the transition to malignancy involves inactivation of p53 (through mutation or HPV involvement in rare cases), PTEN loss, and inactivation of other apoptotic regulators, allowing initial expansion of malignant clones. Conversely, this retained chemosensitivity (mediated by wild-type p53 in most cases) explains the remarkable responsiveness to platinum-based chemotherapy and represents a distinguishing feature that enables cure in advanced disease—a finding unique among solid malignancies.

• Angiogenesis and microenvironment remodeling: Developing testicular tumors trigger extensive neoangiogenesis through VEGF and HIF-1α signaling, creating a permissive microenvironment for local invasion and metastatic dissemination. Stromal cells, cancer-associated fibroblasts, and immune infiltrates are remodeled to support tumor growth and suppress anti-tumor immunity. This microenvironment is increasingly recognized as important in chemotherapy response and relapse mechanisms.

• Cryptorchidism (undescended testis): Represents the strongest established risk factor for testicular cancer, conferring a 4–8 fold increased relative risk. The mechanism involves impaired testicular development, abnormal temperature regulation (intrascrotal temperature is critical for normal spermatogenesis and germ cell development), disrupted signaling between germ cells and Sertoli cells, and possible direct effects of the abnormal gonadal microenvironment. Importantly, orchiopexy (surgical correction) performed even in childhood does not eliminate the cancer risk, suggesting that the critical injury occurs during embryonic or early postnatal development before descent. The undescended testis carries increased risk, and notably, the contralateral normally descended testis also carries modestly increased risk (2–3 fold), indicating that cryptorchidism may be a manifestation of underlying systemic germ cell developmental abnormality rather than purely a local mechanical effect. Risk is greater for intra-abdominal cryptorchidism than inguinal cryptorchidism.

• Personal or family history of testicular germ cell tumor: Men with a history of germ cell tumor in one testis carry a 100–500 fold increased risk of developing cancer in the contralateral testis (cumulative incidence ~2–5% at 25 years). This markedly elevated risk reflects the probability that the same developmental abnormality affecting the first testis also affects the contralateral gonad. Additionally, first-degree relatives of men with testicular cancer have a 4–8 fold increased risk, and familial clustering has been documented, suggesting genetic predisposition (though specific high-penetrance genes remain incompletely identified; some associations with KITLG and DMRT1 polymorphisms have been reported). This familial risk likely reflects shared genetic susceptibility to IGCNU development and progression.

• Infertility and gonadal dysfunction: Men with infertility, especially azoospermia or oligozoospermia, show increased testicular cancer incidence independent of treatment. This association suggests shared underlying gonadal dysgenesis or developmental abnormalities that predispose to both infertility and malignancy. Gonadal dysgenesis, including conditions like Klinefelter syndrome (XXY karyotype), confer substantially increased cancer risk through mechanisms involving abnormal germ cell development and IGCNU formation.

• Race and ethnicity: Testicular cancer incidence is highest in Caucasian populations (5–6 per 100,000) and lower in African, Hispanic, and Asian populations (1–3 per 100,000), suggesting genetic and possibly environmental factors. The basis for this difference remains incompletely understood but may involve differences in frequency of IGCNU, cryptorchidism prevalence, or genetic susceptibility alleles.

• Age and pubertal development timing: Peak incidence occurs in young adulthood (20–40 years), with a second smaller peak in men over 60 (predominantly lymphomas of testis). Earlier puberty and testicular volume changes have been associated with increased cancer risk, suggesting that hormonal milieu during critical developmental windows influences germ cell malignant transformation.

• Maternal hormone exposure and intrauterine factors: Retrospective studies have suggested associations between maternal estrogen and hormone use during pregnancy and subsequent testicular cancer risk in offspring, though evidence remains inconsistent. The hypothesis involves estrogenic effects on fetal germ cell development and IGCNU formation in utero.

• Testicular intra-epithelial neoplasia (TIN)/IGCNU in contralateral testis: While not a primary cause, the presence of IGCNU in testicular biopsies is a strong predictor of progression to invasive cancer, with approximately 50% of men with IGCNU progressing to invasive cancer within 5 years. This has implications for surveillance and potential preventive intervention in high-risk populations.

• Testicular mass or enlargement (cardinal presenting symptom): The most common presentation is discovery of a unilateral testicular mass or focal enlargement, usually noted incidentally during self-examination or routine physical examination. Approximately 70–80% of men with testicular cancer present with a painless testicular mass. The mass is typically firm, non-transilluminable (distinguishing it from hydrocele or spermatocele), and fixed to surrounding tissues. Patients often report noticing the mass weeks to months before seeking medical evaluation. The physiological basis involves progressive expansion of malignant cells within seminiferous tubules, disruption of normal testicular architecture, and replacement of functional parenchyma with neoplastic tissue. The lack of pain in many cases reflects the fact that malignant growth is often gradual and testicular tissue lacks the sensitivity to distension that other organs possess.

• Testicular pain or discomfort: Approximately 10–30% of men present with acute or subacute testicular pain or heaviness. This may result from hemorrhage within the tumor, rapid expansion stretching the tunica albuginea (which is richly innervated), inflammatory response to the malignancy, or infarction of tumor tissue. Importantly, acute testicular pain can represent testicular torsion (a surgical emergency) or epididymitis, and testicular cancer must be excluded in any young man presenting with testicular pain, even if initial concern is for torsion. The classic presentation of cancer (painless mass) can be delayed while treatable conditions are managed, emphasizing the importance of ultrasonography in all cases of testicular pain.

• Gynecomastia (breast tenderness and enlargement): Present in 5–10% of men with testicular cancer, primarily those with choriocarcinoma or mixed tumors producing β-hCG. The physiological mechanism involves hCG-stimulated peripheral conversion of androgens to estrogens via aromatase in adipose tissue, or direct estrogenic effects of tumor products. Gynecomastia in a young man should raise suspicion for testicular cancer (or other hCG-producing malignancies), and the presence of gynecomastia associated with a testicular mass is highly suggestive of choriocarcinoma or mixed germ cell tumor.

• Systemic symptoms from advanced disease: Men presenting with metastatic disease (20–30% at initial presentation) may have constitutional symptoms including weight loss, fatigue, low-grade fevers, and night sweats reflecting tumor burden and metabolic effects. Some patients present with symptoms referable to metastatic sites before awareness of primary testicular disease, such as abdominal/flank pain from retroperitoneal lymphadenopathy, chest pain or dyspnea from pulmonary metastases, or neurological symptoms from brain metastases.

• Acute abdominal or flank pain from hemorrhage: Spontaneous rupture of a testicular tumor with intra-abdominal bleeding is rare but can present as acute abdomen. More commonly, pain results from retroperitoneal lymph node metastases or their complications (hemorrhage, necrosis).

• Back pain from retroperitoneal lymphadenopathy: Common in advanced disease, often the presenting symptom in men with occult primary tumors or who delay presentation. Retroperitoneal adenopathy can reach massive proportions (>10 cm) before causing symptoms, or may compress local structures (ureter, intestine).

• Physical examination with attention to testicular consistency and size: The first diagnostic step is careful bimanual palpation of both testes comparing size, consistency, and nodularity. A testicular mass should be characterized as firm, non-transilluminable, fixed, and typically arising from within the testicular parenchyma rather than the epididymis (though distinguishing these can be difficult clinically). Transillumination is a key examination maneuver: benign collections of fluid (hydrocele, spermatocele) transilluminate brightly, while solid masses and blood-filled collections do not. The presence of a non-transilluminable mass is highly suspicious for cancer. Palpate the lymph nodes in inguinal and supraclavicular regions and perform abdominal examination for masses or tenderness. Always examine the contralateral testis given the increased cancer risk.

• Scrotal ultrasonography (sensitivity >95%, specificity ~90%): Scrotal ultrasound with both grayscale and Doppler imaging is the gold standard diagnostic imaging modality and should be performed urgently in any man with a palpable testicular abnormality or clinical suspicion of malignancy. Benign intratesticular masses (cysts, adenomatoid tumors, epidermoid cysts) have characteristic ultrasonographic appearances. Testicular cancer typically appears as a hypoechoic or isoechoic intratesticular mass, often with increased vascularity on color Doppler (increased blood flow relative to normal testicular tissue). Absence of a visualized mass on ultrasound essentially excludes testicular cancer with high confidence. Ultrasound also assesses the contralateral testis and can detect hydrocele or epididymal abnormalities. Some specialists advocate for contralateral testicular biopsy in high-risk patients (cryptorchidism, family history, infertility) to detect occult IGCNU, though this remains controversial and is not standard practice.

• Tumor markers (AFP, β-hCG, LDH) obtained before orchiectomy: Serum markers are essential for diagnosis confirmation, prognosis assessment, and surveillance. Obtain baseline serum AFP, β-hCG, and LDH before any intervention (including inguinal orchiectomy) to establish prognostic risk group. Half-lives: AFP ~5–7 days, β-hCG ~24–36 hours, LDH ~24 hours. Normal values: AFP <20 ng/mL, β-hCG <5 mIU/mL, LDH <480 IU/L (varies by lab). Elevated preoperative markers indicate tumor production: AFP is produced by ~50% of non-seminomatous germ cell tumors (yolk sac tumor, embryonal carcinoma, mixed tumors) and is virtually never produced by pure seminoma or choriocarcinoma (which produce β-hCG instead). β-hCG is produced by ~40% of non-seminomatous tumors (primarily choriocarcinoma and mixed tumors with trophoblastic component) and is elevated in ~20% of pure seminomas. LDH elevation correlates with tumor burden and is less specific (elevation occurs in any histology but is more frequent in seminoma with advanced disease). Marker elevation postoperatively with prior preoperative normality suggests chemotherapy responsiveness and potential for cure; marker normalization after chemotherapy is favorable prognostic sign; persistent marker elevation after chemotherapy predicts chemotherapy-resistant disease and treatment failure.

• Inguinal radical orchiectomy with high ligation of spermatic cord (definitive tissue diagnosis and primary treatment): Radical inguinal orchiectomy is both diagnostic and therapeutic, providing tissue for histopathological diagnosis while removing the primary tumor. This must be performed via an inguinal approach with early control and ligation of the spermatic cord above the internal ring to prevent iatrogenic tumor spillage and hematogenous dissemination; a scrotal approach is absolutely contraindicated. Pathological examination determines histology (seminoma vs. specific NSGCT components), grade, stage, vascular invasion status, and IGCNU presence in adjacent parenchyma. Frozen section intraoperatively is not routinely needed.

• Retroperitoneal imaging (CT abdomen/pelvis) for staging: After tissue diagnosis, CT of the abdomen and pelvis with intravenous contrast is essential for staging, identifying retroperitoneal lymph node metastases (threshold typically >1 cm short axis in single plane or >1 cm on any view as abnormal, though some centers use size criteria of >1.5 cm). CT cannot reliably detect retroperitoneal involvement <1 cm, and 15–20% of clinical stage I patients harbor occult

Initial and definitive local therapy

• Radical inguinal orchiectomy: the first therapeutic act for essentially every patient, performed with high ligation of the cord at the internal ring. Per NCCN and AUA guidance, a trans-scrotal approach or percutaneous biopsy is contraindicated because it violates lymphatic planes and diverts drainage to inguinal nodes, altering staging and risking local recurrence.
• Sperm banking before any chemotherapy, radiation, or retroperitoneal surgery: ASCO fertility-preservation guidance makes this a pre-treatment discussion, not an afterthought.
• Emergent situations: bulky mediastinal or retroperitoneal disease causing airway compromise, cord compression, or ureteral obstruction, and hemorrhagic choriocarcinoma metastases, require urgent chemotherapy (often before orchiectomy) rather than surgery first.

Stage I disease (NCCN risk-adapted)

• Active surveillance: preferred for both stage I seminoma and stage I NSGCT, with serial markers and imaging, because salvage cure rates approach those of upfront adjuvant therapy.
• Adjuvant alternatives: single-agent carboplatin (dosed by AUC) or low-dose para-aortic radiation for seminoma; one cycle of BEP or nerve-sparing retroperitoneal lymph node dissection (RPLND) for NSGCT, especially with lymphovascular invasion.

Advanced/metastatic disease

• Platinum-based combination chemotherapy is the backbone: BEP (bleomycin, etoposide, cisplatin), three cycles for IGCCCG good-risk and four for intermediate/poor-risk disease; EP (four cycles) substitutes when bleomycin is unwise (impaired renal function, underlying lung disease, older age).
• Post-chemotherapy residual masses: in NSGCT, a residual mass larger than roughly a centimeter warrants surgical resection (RPLND) because teratoma and viable tumor are chemoresistant. In seminoma, FDG-PET performed several weeks after chemotherapy guides whether resection or observation is appropriate.
• Relapse/salvage: cisplatin-based salvage regimens such as TIP (paclitaxel, ifosfamide, cisplatin) or high-dose chemotherapy with autologous stem cell rescue.

Disease-related

• Bulky retroperitoneal nodal disease: compresses ureters (hydronephrosis, rising creatinine) or the IVC (leg edema, venous thrombus, pulmonary embolism). Ureteral obstruction with infection or acute kidney injury is an emergency.
• Choriocarcinoma hemorrhage: syncytiotrophoblastic metastases are highly vascular and bleed into brain and lung. Hemoptysis, sudden headache, or focal deficit in a young man with a very high β-hCG is an emergency; massive hemorrhage may be precipitated by starting chemotherapy (choriocarcinoma syndrome).
• Spinal cord compression from vertebral or epidural extension — back pain with neurologic signs demands immediate imaging and corticosteroids.
• hCG-mediated endocrinopathy: the shared alpha subunit cross-stimulates the TSH receptor, producing biochemical hyperthyroidism; gynecomastia arises via aromatization.

Treatment-related

• Bleomycin pulmonary toxicity: free-radical injury in lung tissue, which is deficient in bleomycin hydrolase, causes pneumonitis progressing to fibrosis. Signal: dry cough, exertional dyspnea, falling DLCO, basilar reticular changes. High inspiratory oxygen concentrations perioperatively can precipitate acute decompensation — an anesthesia emergency.
• Cisplatin toxicity: cumulative nephrotoxicity with magnesium wasting, high-frequency sensorineural hearing loss and tinnitus, peripheral sensory neuropathy, and Raynaud phenomenon.
• Etoposide: topoisomerase II inhibition yields balanced 11q23 (MLL/KMT2A) translocations and secondary acute myeloid leukemia with a characteristically short latency.
• RPLND: injury to postganglionic sympathetic fibers of the hypogastric plexus causes retrograde ejaculation and infertility; nerve-sparing technique mitigates this.
• Radiation: second solid malignancies (notably gastrointestinal) decades later.
• Growing teratoma syndrome: an enlarging mass with normal markers during or after chemotherapy — chemoresistant, requires resection.
• Late effects: hypogonadism, metabolic syndrome, and increased cardiovascular risk in long-term survivors; febrile neutropenia during chemotherapy is always an emergency.

• Single best next step: a firm, painless, non-transilluminating intratesticular mass in a man 15–35 years old gets scrotal ultrasound, then serum AFP, β-hCG, and LDH, then radical inguinal orchiectomy. Never trans-scrotal biopsy or FNA — the classic wrong answer.
• AFP is never produced by pure seminoma or by pure choriocarcinoma. If the pathology says seminoma but the AFP is elevated, the tumor is managed as a non-seminoma. This is the single most frequently tested marker rule.
• Histology buzzwords: fried-egg clear cells with fibrous septa and lymphocytic infiltrate = seminoma; Schiller-Duval bodies (glomeruloid structures) = yolk sac tumor, the most common testicular tumor of infancy; syncytiotrophoblasts plus cytotrophoblasts with hemorrhage and necrosis = choriocarcinoma; isochromosome 12p = germ cell tumor of any subtype.
• The association examiners love: Reinke crystals = Leydig cell tumor, presenting with precocious puberty in boys or gynecomastia in adults. Distractor to avoid: Call-Exner bodies belong to ovarian granulosa cell tumors, not testis.
• Lymphatic drainage follows embryologic descent: testicular tumors spread to para-aortic/retroperitoneal nodes, not inguinal nodes. Inguinal adenopathy suggests prior scrotal violation or scrotal skin involvement. Left-sided disease can track to the left supraclavicular node.
• Seminoma is exquisitely radiosensitive and chemosensitive; NSGCT is not radiosensitive — radiation is not offered for NSGCT.
• Cryptorchidism raises risk in both testes, and orchiopexy does not abolish it — it does, however, make the testis examinable.
• Age flip: a testicular mass in a man over 60, especially bilateral, is most likely diffuse large B-cell lymphoma, not a germ cell tumor.
• Gynecomastia plus a testicular mass points to β-hCG production (choriocarcinoma or mixed tumor).